Intellia Therapeutics (NTLA) Insider Trading & Ownership $11.46 +0.09 (+0.79%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.70 +0.24 (+2.06%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Intellia Therapeutics (NASDAQ:NTLA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$546.89K Get NTLA Insider Trade Alerts Want to know when executives and insiders are buying or selling Intellia Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NTLA Insider Buying and Selling by Quarter Intellia Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/23/2025Edward J Dulac IIIEVPSell7,462$14.02$104,617.24 7/2/2025Michael P DubeCAOSell2,503$9.95$24,904.85 7/1/2025Eliana ClarkEVPSell1,022$9.82$10,036.04 7/1/2025Jesse GoodmanDirectorSell1,547$9.23$14,278.81 4/29/2025Muna BhanjiDirectorSell265$8.50$2,252.50 1/29/2025Muna BhanjiDirectorSell265$9.97$2,642.05 1/3/2025John M LeonardCEOSell26,807$12.18$326,509.26 1/3/2025Michael P DubeCAOSell1,372$12.18$16,710.96 1/2/2025Eliana ClarkEVPSell556$12.03$6,688.68 10/2/2024Michael P DubeCAOSell2,012$19.01$38,248.12 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. (Data available from 1/1/2013 forward) NTLA Insider Trading Activity - Frequently Asked Questions Who is on Intellia Therapeutics' Insider Roster? The list of insiders at Intellia Therapeutics includes David Lebwohl, Edward J Dulac III, Eliana Clark, Glenn Goddard, James Basta, Jesse Goodman, John M Leonard, Laura Sepp-Lorenzino, Michael P Dube, and Muna Bhanji. Learn more on insiders at NTLA. What percentage of Intellia Therapeutics stock is owned by insiders? 3.10% of Intellia Therapeutics stock is owned by insiders. Learn more on NTLA's insider holdings. Which Intellia Therapeutics insiders have been selling company stock? The following insiders have sold NTLA shares in the last 24 months: David Lebwohl ($172,134.78), Edward J Dulac III ($104,617.24), Eliana Clark ($26,011.37), Glenn Goddard ($158,052.90), James Basta ($75,778.03), Jesse Goodman ($14,278.81), John M Leonard ($892,818.84), Laura Sepp-Lorenzino ($65,679.25), Michael P Dube ($79,863.93), and Muna Bhanji ($11,228.05). How much insider selling is happening at Intellia Therapeutics? Insiders have sold a total of 79,484 Intellia Therapeutics shares in the last 24 months for a total of $1,600,463.20 sold. Intellia Therapeutics Key ExecutivesDr. John M. Leonard M.D. (Age 67)President, CEO & Director Compensation: $1.06MMr. Glenn G. Goddard CPA (Age 53)Executive VP, CFO & Treasurer Compensation: $630.91kDr. Laura Sepp-Lorenzino Ph.D. (Age 63)Executive VP & Chief Scientific Officer Compensation: $670.58kMr. James E. Basta Esq. (Age 58)J.D., Executive VP, General Counsel & Corporate Secretary Compensation: $616.15kDr. David Lebwohl M.D. (Age 69)Executive VP & Chief Medical Officer Compensation: $671.42kMr. Derek Hicks (Age 50)Executive VP & Chief Business Officer Compensation: $823.42kMr. Nessan Bermingham Ph.D. (Age 51)Founder & Member of Scientific Advisor Board Compensation: $1.38MDr. Rachel E. Haurwitz Ph.D. (Age 38)Co-Founder Dr. Andrew May Ph.D.Founder and Member of Scientific Advisor BoardDr. Jennifer A. Doudna Ph.D. (Age 60)Founder & Member of Scientific Advisor Board More Insider Trading Tools from MarketBeat Related Companies Beam Therapeutics Insider Selling CRISPR Therapeutics Insider Selling Editas Medicine Insider Selling Lantheus Insider Selling Axsome Therapeutics Insider Selling Vaxcyte Insider Selling Merus Insider Selling Krystal Biotech Insider Selling Cytokinetics Insider Selling Zai Lab Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:NTLA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
